CLYBL: A Drug Target / Disease Biomarker (G171425)

Target Name: CLYBL

NCBI ID: G171425

CLYBL

CLYBL: A Drug Target / Disease Biomarker

CLYBL is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and muscle. It is a member of the GLUTAMyltransferase (GLT) family, which is a group of transmembrane proteins that transfer amino acids from the cytosol to the extracellular space via glutamyl-containing transmembrane channels.

CLYBL is unique among its family members because of its unique subcellular localization. Unlike other GLTs, which are mainly cytoplasmic, CLYBL is predominantly nuclear. This nuclear localization is important for its function in cell signaling, as nuclear proteins are involved in a wide range of cellular processes, including DNA replication, gene expression, and signaling pathways.

CLYBL plays a key role in the regulation of cellular signaling pathways, particularly those that are involved in the development and maintenance of tissues and organs. One of its well-established functions is its role in the development and maintenance of the myocardium, which is the heart muscle. CLYBL has been shown to be involved in the regulation of myocardial gene expression, cell signaling pathways, and cellular mechanics.

In addition to its role in myocardial development and maintenance, CLYBL is also involved in the regulation of other tissues and organs. For example, it has been shown to be involved in the development and maintenance of the liver, and it has been shown to play a role in the regulation of insulin sensitivity in the obesity-diabetic rat.

The potential drug targets for CLYBL are vast, as its involvement in a wide range of cellular processes makes it an attractive target for intervention. Some potential drug targets for CLYBL include inhibitors of its activity, modulators of its expression, and alterations in its localization.

One potential drug target for CLYBL is inhibitors of its activity. These inhibitors could be used to treat a wide range of diseases, including heart disease, diabetes, and cancer. By inhibiting the activity of CLYBL, drugs could be developed that improve cellular signaling pathways and help to prevent the development and progression of these diseases.

Another potential drug target for CLYBL is modulators of its expression. These modulators could be used to either increase or decrease the amount of CLYBL that is expressed in cells, depending on the desired effect. For example, modulators of CLYBL expression could be used to increase the amount of CLYBL that is expressed in the heart muscle, which could help to improve cardiac function and reduce the risk of heart disease.

Another potential drug target for CLYBL is alterations in its localization.CLYBL is predominantly nuclear, but it can also be localized to the cytoplasm. Researchers are studying how alterations in CLYBL localization can affect its function, and the potential therapeutic benefits of these alterations.

In conclusion, CLYBL is a protein that is involved in a wide range of cellular processes throughout the body. Its unique nuclear localization and its involvement in the regulation of cellular signaling pathways make it an attractive target for drug intervention. The potential drug targets for CLYBL are vast and continue to be explored by researchers. Further studies are needed to fully understand the function of CLYBL and its potential as a drug target.

Protein Name: Citramalyl-CoA Lyase

Functions: Mitochondrial citramalyl-CoA lyase indirectly involved in the vitamin B12 metabolism (PubMed:29056341). Converts citramalyl-CoA into acetyl-CoA and pyruvate in the C5-dicarboxylate catabolism pathway (PubMed:29056341). The C5-dicarboxylate catabolism pathway is required to detoxify itaconate, a vitamin B12-poisoning metabolite (PubMed:29056341). Also acts as a malate synthase in vitro, converting glyoxylate and acetyl-CoA to malate (PubMed:29056341, PubMed:24334609). Also displays malyl-CoA thioesterase activity (PubMed:29056341). Also acts as a beta-methylmalate synthase in vitro, by mediating conversion of glyoxylate and propionyl-CoA to beta-methylmalate (PubMed:24334609, PubMed:29056341). Also has very weak citramalate synthase activity in vitro (PubMed:24334609, PubMed:29056341)

The "CLYBL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLYBL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets